BIOXXMED AG, a biotechnology company headquartered in Germany, has been making strides in the healthcare sector with its focus on developing innovative treatments for chronic wounds, vascular diseases, and cancer. The company operates within the biotechnology industry and is listed on the Frankfurt Stock Exchange, specifically on the Xetra platform. As of July 16, 2026, BIOXXMED AG’s close price stood at 0.83 EUR, reflecting a significant fluctuation over the past year, with a 52-week high of 2.75 EUR on August 19, 2025, and a low of 0.005 EUR on November 19, 2025. The company’s market capitalization is currently valued at 225,650 EUR.
BIOXXMED AG’s primary focus is on the discovery and development of small molecules and biologics, aiming to address unmet medical needs in the treatment of chronic wounds, vascular diseases, and cancer. This strategic focus positions the company at the forefront of biotechnological advancements in these critical areas of healthcare. The company’s efforts are directed towards serving its German customer base, with its online presence maintained through cytotools.de.
Financially, BIOXXMED AG has faced challenges, as indicated by its price-to-earnings ratio of -0.6. This negative ratio suggests that the company is currently not generating profits, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development. The sector often requires substantial upfront investment before achieving profitability, and BIOXXMED AG is no exception.
Despite these financial challenges, BIOXXMED AG continues to pursue its mission of developing groundbreaking treatments. The company’s commitment to innovation and addressing critical healthcare needs underscores its potential for future growth and success. As it navigates the complexities of the biotechnology industry, BIOXXMED AG remains focused on its strategic objectives, aiming to make significant contributions to the treatment of chronic wounds, vascular diseases, and cancer.
